The brand product has annual sales of $4.6 billion in the US.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced today that it has extended the commercial launch in the US of Quetiapine Fumarate tablets, the company’s generic version of AstraZeneca’s schizophrenia treatment, Seroquel tablets.
The brand product has annual sales of $4.6 billion in the US, based on IMS sales data.
Yesterday, Teva announced the launch of the generic drug in the UK where annual sales of Seroquel are estimated at $1.49 billion.
Published by Globes, Israel business news - www.globes-online.com - on March 28, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012